Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this retrospective study is to evaluate the long-term clinical outcomes and complications associated with amygdalo-hippocampectomy using the surgical technique developed by Pr. Coubes (Montpellier, FRANCE). The main questions it aims to answer are:
Participants include 234 patients treated over the last 30 years at the CHU de Montpellier, FRANCE. The study will analyze clinical data, including seizure outcomes based on ILAE criteria, post-operative complications, and factors influencing recovery and reintegration into daily life.
Title Exploration and Evaluation of Amygdalo-Hippocampectomy Using Pr. Coubes' Technique: An Anatomical, Clinical, and Pedagogical Approach
Introduction The hippocampus, a vital component of the limbic system, plays a key role in memory and emotions. Unfortunately, it is also prone to various pathologies, such as hippocampal sclerosis, a condition characterized by progressive neuronal degeneration and subsequent fibrosis of the medial temporal lobe. Other diseases may occur such as tumours, Dysembryoplastic Neuroepithelial Tumour (DNET) or gliomas.
This condition often leads to severe symptoms, including pharmacoresistant epilepsy and memory disturbances that significantly impair the quality of life.
For patients with pharmacoresistant epilepsy associated with hippocampal sclerosis, surgery has emerged as a first-line therapeutic option. Among the surgical techniques, hippocampectomy and amygdalo-hippocampectomy aim to remove the affected portion of the hippocampus, reducing seizure propagation and improving patient outcomes. However, these procedures are marked by significant variability in their operative techniques, extents of resection, and patient selection criteria.
While the amygdalo-hippocampectomy technique described by Pr. Yasargil in 1985 remains a cornerstone in surgical approaches, other methods such as the trans-sylvian approach (Adada et al., 2008), the trans-gyral approach (Mathon & Clemenceau, 2016), and emerging endoscopic techniques (H. Westley Phillips, 2023) highlight the diversity and evolution of surgical options.
This study seeks to explore in detail the surgical technique developed by Pr. Coubes, analyzing its anatomical, surgical, and clinical aspects. Additionally, it aims to compare this method with other surgical approaches to understand its benefits and limitations better in managing hippocampal sclerosis.
Objectives Primary Objective
- To describe the complications and the evolution of clinical outcomes in patients treated with Pr. Coubes' amygdalo-hippocampectomy technique.
Secondary Objective - To identify variables associated with favorable seizure control and overall clinical outcomes.
Study Design Type of Study
- Retrospective, single-center study conducted at the CHU de Montpellier.
Population
Data Collection
Methodology Statistical Analysis
Outcome Measures
Ethical Considerations
Expected Contributions
Conclusion This study represents a unique opportunity to document and analyze a long-practiced yet unpublished surgical technique. By consolidating decades of clinical experience and integrating advanced analytical methods, it aims to provide valuable insights for improving the management of hippocampal sclerosis, ultimately advancing patient care and surgical education.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients operated | We studied all the patients who underwent an Amygdalo-Hippocampectomy in the University Hospital of Montpellier, France from 1995 until 2022 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Amygdalo-Hippocampectomy | Procedure | This technique is characterized by specific hallmarks that distinguish it from other approaches, including the Yasargil technique and newer minimally invasive methods. It integrates precise anatomical targeting with optimized surgical pathways to enhance outcomes in patients with those pathologies. The approach of the choroidal fissure will be explained in the article. By addressing limitations observed in traditional techniques, it aims to minimize neurological deficits while achieving better seizure control. |
| Measure | Description | Time Frame |
|---|---|---|
| Post-Surgical Classification assessing epilepsy's control | The ILAE post-surgical classification system is used to categorize seizure outcomes after epilepsy surgery. It provides a standardized way to evaluate how effectively surgery controls seizures, enabling consistency in reporting and comparison of surgical outcomes across studies and clinical settings. In those cases of drug-resistance epilepsy, we will assess the epilepsy's control after the surgery.
| From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to twenty years. The study starts in 2024 and ends in 2025, which lasts one year. |
| Measure | Description | Time Frame |
|---|---|---|
| Post-operative complications : Infections | Each post-operative complications have been studied during the medical follow-up. It included the immediate post-operative complications such as presence of an infection. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to twenty years. The study starts in 2024 and ends in 2025, which lasts one year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
All the patients that have been followed in the University Hospital of Montpellier, France in the Epileptic Ward.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Pierre-Olivier MOSER, Medical Doctor | Contact | +33 7 60 13 54 37 | po-moser@chu-montpellier.fr | |
| Gaetan POULEN, MD, PhD | Contact | +33 6 31 81 26 05 | g-poulen@chu-montpellier.fr |
| Name | Affiliation | Role |
|---|---|---|
| Gaetan POULEN, MD, PhD | CHU de MONTPELLIER, FRANCE | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Montpellier | Recruiting | Montpellier | Hérault | 34000 | France |
Not provided
Not provided
Not provided
Not provided
|
| Post-operative complications : Hematomas | Each post-operative complications have been studied during the medical follow-up. It included the immediate post-operative complications such as presence of hematoma. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to twenty years. The study starts in 2024 and ends in 2025, which lasts one year. |
| Post-operative way of life | As part of this research on the surgery, the investigators are studying the post-surgical way of life of patients who have undergone this procedure. This includes evaluating various aspects of their daily functioning, such as autonomy, cognitive and psychiatric outcomes, social integration, and overall quality of life. By analyzing these factors, the investigators aim to better understand the long-term impact of hippocampectomy and identify potential areas for improving patient care and rehabilitation strategies. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to twenty years. The study starts in 2024 and ends in 2025, which lasts one year. |
| Risk factors or predisposing factors of success or failure after Amygdalo-Hippocampectomy | Among the patients who underwent favourable and unfavourable evolutions, we will assess the risk factors and the predisposing factors such as febrile seizure, medical history, etiologic lesions. | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to twenty years |
| Anti-Seizures Medications (ASM) evolution after the surgery | The investigators have also compared the potential evolution of the medications after the surgery given the drug-resistance profil of these patients. The number of tablets have been reported before the surgery and at the last medical follow-up. | Medication prescribed before the surgery and medication prescribed at the last medical follow-up, assessed up to twenty years |
| ID | Term |
|---|---|
| D000092223 | Hippocampal Sclerosis |
| D054220 | Malformations of Cortical Development |
| D018303 | Ganglioglioma |
| D018324 | Hemangioma, Capillary |
| D004814 | Epidermal Cyst |
| D006222 | Hamartoma |
| D001254 | Astrocytoma |
| ID | Term |
|---|---|
| D065703 | Malformations of Cortical Development, Group I |
| D009421 | Nervous System Malformations |
| D009422 | Nervous System Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D005910 | Glioma |
| D018302 | Neoplasms, Neuroepithelial |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009380 | Neoplasms, Nerve Tissue |
| D006391 | Hemangioma |
| D009383 | Neoplasms, Vascular Tissue |
| D003560 | Cysts |
Not provided
Not provided